trimetazidine has been researched along with Carcinoma, Anaplastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdeljalil, SM; Elghazaly, H; Tolba, MF; Wahdan, SA | 1 |
| Aboslema, RF; El-Sayed, NM; Elsayed, M; Hazem, RM; Kishk, SM; Mehanna, ET | 1 |
2 other study(ies) available for trimetazidine and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Insights into the therapeutic outcomes of trimetazidine/doxorubicin combination in Ehrlich solid-phase carcinoma mouse tumor model.
Topics: Animals; Apoptosis; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Doxorubicin; Female; Humans; Mice; Treatment Outcome; Trimetazidine | 2023 |
Antitumor effect of trimetazidine in a model of solid Ehrlich carcinoma is mediated by inhibition of glycolytic pathway and AKT signaling.
Topics: Animals; Carcinoma; Mice; Molecular Docking Simulation; Proto-Oncogene Proteins c-akt; Trimetazidine; Tumor Suppressor Protein p53 | 2023 |